Profile data is unavailable for this security.
About the company
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
- Revenue in USD (TTM)8.00k
- Net income in USD-25.78m
- Incorporated2001
- Employees23.00
- LocationGenelux Corp2625 Townsgate Road, Suite 230WESTLAKE VILLAGE 91361United StatesUSA
- Phone+1 (805) 267-9889
- Fax+1 (302) 636-5454
- Websitehttps://genelux.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prenetics Global Ltd | 22.25m | -49.97m | 68.42m | 320.00 | -- | 0.2987 | -- | 3.07 | -4.33 | -5.32 | 1.91 | 18.75 | 0.0832 | 3.89 | 4.53 | 69,535.41 | -19.43 | -- | -23.55 | -- | 45.56 | -- | -233.41 | -- | 2.25 | -5.17 | 0.0086 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| Precision BioSciences Inc | 57.53m | -19.99m | 68.91m | 109.00 | -- | 1.85 | -- | 1.20 | -5.50 | -7.41 | 13.76 | 5.38 | 0.2956 | -- | 47.10 | 527,807.30 | -10.27 | -35.35 | -12.94 | -44.22 | -- | -- | -34.74 | -147.50 | -- | -- | 0.3764 | -- | 94.15 | 34.96 | 41.67 | -- | -32.01 | -- |
| vTv Therapeutics Inc | 1.00m | -20.62m | 70.77m | 16.00 | -- | 3.40 | -- | 70.77 | -8.76 | -8.76 | 0.383 | 6.91 | 0.0241 | -- | 2.04 | 62,500.00 | -63.15 | -111.84 | -128.59 | -- | -- | -- | -2,621.10 | -680.94 | -- | -- | 0.00 | -- | -100.00 | -- | -5.67 | -- | -- | -- |
| Cognition Therapeutics Inc | 0.00 | -28.77m | 71.70m | 25.00 | -- | 2.48 | -- | -- | -0.9155 | -0.9155 | 0.00 | 0.7218 | 0.00 | -- | -- | 0.00 | -68.08 | -- | -85.18 | -- | -- | -- | -- | -- | -- | -251.59 | 0.00 | -- | -- | -- | -20.52 | -- | -- | -- |
| Connect Biopharma Holdings Ltd (ADR) | 0.00 | -59.50m | 72.74m | 81.00 | -- | 0.7513 | -- | -- | -1.08 | -1.08 | 0.00 | 1.76 | -- | -- | -- | 0.00 | -- | -66.24 | -- | -71.36 | -- | -- | -- | -- | -- | -- | 0.0046 | -- | -- | -- | 49.61 | -- | 10.32 | -- |
| Genelux Corp | 8.00k | -25.78m | 74.20m | 23.00 | -- | 3.80 | -- | 9,275.03 | -0.9811 | -0.9811 | 0.0003 | 0.5679 | 0.0004 | -- | -- | 347.83 | -131.24 | -- | -246.21 | -- | -- | -- | -322,287.50 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
| Ovid Therapeutics Inc | 473.53k | -50.68m | 74.49m | 40.00 | -- | 0.9495 | -- | 157.31 | -0.7174 | -0.7174 | 0.0067 | 1.11 | 0.0034 | -- | -- | 11,838.25 | -36.86 | -20.78 | -39.08 | -23.27 | -- | -- | -10,701.91 | -56.16 | -- | -- | 0.00 | -- | -73.93 | -- | 3.38 | -- | -17.14 | -- |
| Spero Therapeutics Inc | 110.98m | 23.40m | 74.50m | 46.00 | 3.28 | 0.7724 | 3.14 | 0.6713 | 0.4213 | 0.4213 | 2.08 | 1.79 | 0.792 | -- | 3.96 | 2,412,565.00 | 16.70 | -35.52 | 21.73 | -41.75 | -- | -- | 21.09 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Gritstone bio Inc | 15.65m | -144.89m | 75.17m | 231.00 | -- | 4.86 | -- | 4.80 | -1.57 | -1.57 | 0.17 | 0.1423 | 0.0901 | -- | 40.53 | 67,727.27 | -83.47 | -48.08 | -97.70 | -55.18 | -- | -- | -926.13 | -573.71 | -- | -554.88 | 0.7428 | -- | -18.05 | 68.96 | -15.71 | -- | -4.19 | -- |
| Allakos Inc | 0.00 | -214.44m | 75.26m | 131.00 | -- | 0.7173 | -- | -- | -2.45 | -2.45 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -81.27 | -42.71 | -92.78 | -45.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 41.96 | -- | -38.89 | -- |
| enVVeno Medical Corp | 0.00 | -22.12m | 75.85m | 31.00 | -- | 1.79 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| MDxHealth SA | 75.33m | -39.90m | 76.00m | 300.00 | -- | -- | -- | 1.01 | -1.41 | -1.41 | 2.84 | -0.0357 | 0.5528 | 11.06 | 6.95 | 251,090.00 | -29.28 | -51.62 | -33.98 | -64.72 | 62.76 | 50.88 | -52.97 | -117.64 | 1.53 | -1.54 | 1.02 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -55.09m | 79.37m | 47.00 | -- | 1.99 | -- | -- | -1.25 | -1.25 | 0.00 | 0.7498 | 0.00 | -- | -- | 0.00 | -53.21 | -48.44 | -56.51 | -51.56 | -- | -- | -- | -1,267.25 | -- | -- | 0.5592 | -- | -80.00 | -- | -2.22 | -- | 86.23 | -- |
| Serina Therapeutics Inc | 137.00k | -20.96m | 79.85m | 4.00 | -- | -- | -- | 582.83 | -14.07 | -14.07 | 0.0909 | -0.5121 | 0.0117 | -- | 3.86 | 34,250.00 | -179.27 | -194.46 | -- | -- | 67.88 | 85.80 | -15,301.46 | -2,347.36 | -- | -0.9274 | 1.70 | -- | 317.65 | -36.69 | -41.49 | -- | -- | -- |
Data as of Jul 24 2024. Currency figures normalised to Genelux Corp's reporting currency: US Dollar USD
14.19%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.13m | 3.30% |
| Woodward Diversified Capital LLCas of 31 Mar 2024 | 1.09m | 3.16% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.00m | 2.92% |
| Geode Capital Management LLCas of 31 Mar 2024 | 424.27k | 1.24% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 395.02k | 1.15% |
| Millennium Management LLCas of 31 Mar 2024 | 261.80k | 0.76% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 162.49k | 0.47% |
| Provident Wealth Management LLCas of 30 Jun 2024 | 157.14k | 0.46% |
| Charles Schwab Investment Management, Inc.as of 31 Mar 2024 | 152.51k | 0.44% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 100.40k | 0.29% |
More ▼
Data from 31 Mar 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
